Goal and Learning Outcomes

The goal of this bioethics continuing education program is to inform nurses about ethical subjects, such as genetic testing, organ transplantation, and physician-assisted suicide, to help them better serve their patients and communities. After studying the information presented here, you will be able to:
  • Contrast physician-assisted suicide with active euthanasia
  • Explain how death is defined using donation after cardiac death criteria
  • State two ways genetic screening can put a person at risk
  • Identify ethical challenges for nurses caring for patients/families contemplating genetic testing, organ donation or assisted suicide
  • Access resources to educate nurses and the public about ethical issues related to genetic testing, organ donation and assisted suicide
  • Affirm or challenge the claim that all nurses have a responsibility to care for patients with Ebola or other serious, life-threatening diseases

Course Authors

Accreditation Information


In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791



Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses


Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.



None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.